These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

380 related items for PubMed ID: 18471158

  • 1. Nephrotoxicity in the setting of invasive fungal diseases.
    Ullmann AJ.
    Mycoses; 2008; 51 Suppl 1():25-30. PubMed ID: 18471158
    [Abstract] [Full Text] [Related]

  • 2. Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries.
    Ullmann AJ, Sanz MA, Tramarin A, Barnes RA, Wu W, Gerlach BA, Krobot KJ, Gerth WC, Longitudinal Evaluation of Antifungal Drugs (LEAD I) Investigators.
    Clin Infect Dis; 2006 Aug 15; 43(4):e29-38. PubMed ID: 16838223
    [Abstract] [Full Text] [Related]

  • 3. Assessment of nephrotoxicity in patients receiving amphotericin B lipid complex: a pharmacosurveillance study in Spain.
    Aguado JM, Lumbreras C, González-Vidal D, Grupo de Farmacovigilancia de Abelcet.
    Clin Microbiol Infect; 2004 Sep 15; 10(9):785-90. PubMed ID: 15355408
    [Abstract] [Full Text] [Related]

  • 4. [Liposomal amphotericin B in the treatment of severe fungal infections. Results of a clinical cohort trial].
    Rieger CT, Dittmer M, Ostermann H.
    Dtsch Med Wochenschr; 2007 Oct 15; 132(40):2062-6. PubMed ID: 17899499
    [Abstract] [Full Text] [Related]

  • 5. Mechanisms and management of amphotericin B-induced nephrotoxicity.
    Miano-Mason TM.
    Cancer Pract; 1997 Oct 15; 5(3):176-81. PubMed ID: 9171554
    [Abstract] [Full Text] [Related]

  • 6. Implementation of clinical practice policy on the continuous intravenous administration of amphotericin B deoxycholate.
    Maharom P, Thamlikitkul V.
    J Med Assoc Thai; 2006 Nov 15; 89 Suppl 5():S118-24. PubMed ID: 17718252
    [Abstract] [Full Text] [Related]

  • 7. [Safety of long-term administration of conventional amphotericin B in oncology patients].
    Doubek M, Mayer J, Horký D.
    Cas Lek Cesk; 2002 Mar 15; 141(5):156-9. PubMed ID: 11998223
    [Abstract] [Full Text] [Related]

  • 8. Lipid formulations of amphotericin B.
    Dix SP, Andriole VT.
    Curr Clin Top Infect Dis; 2000 Mar 15; 20():1-23. PubMed ID: 10943516
    [Abstract] [Full Text] [Related]

  • 9. Deoxycholate amphotericin B and nephrotoxicity in the pediatric setting.
    Bes DF, Rosanova MT, Sberna N, Arrizurieta E.
    Pediatr Infect Dis J; 2014 Aug 15; 33(8):e198-206. PubMed ID: 24618932
    [Abstract] [Full Text] [Related]

  • 10. Should we continue using amphotericin B deoxycholate for the treatment of fungal infections? Adverse events and clinical outcomes.
    Garbino J, Markham L, Matulionyte R, Rives V, Lew D.
    Scand J Infect Dis; 2006 Aug 15; 38(2):110-3. PubMed ID: 16449001
    [Abstract] [Full Text] [Related]

  • 11. [New aspects in treatment of systemic mycoses].
    Presterl E, Graninger W.
    Wien Klin Wochenschr; 1998 Nov 13; 110(21):740-50. PubMed ID: 9871965
    [Abstract] [Full Text] [Related]

  • 12. Best practice guidelines for the management of adverse events associated with amphotericin B lipid complex.
    Craddock C, Anson J, Chu P, Dodgson A, Duncan N, Gomez C, Mehta J, Sadullah S, Subudhi C, Yin JL.
    Expert Opin Drug Saf; 2010 Jan 13; 9(1):139-47. PubMed ID: 19947901
    [Abstract] [Full Text] [Related]

  • 13. Nephrotoxicity and other adverse events among inpatients receiving liposomal amphotericin B or amphotericin B lipid complex.
    Wade RL, Chaudhari P, Natoli JL, Taylor RJ, Nathanson BH, Horn DL.
    Diagn Microbiol Infect Dis; 2013 Jul 13; 76(3):361-7. PubMed ID: 23774005
    [Abstract] [Full Text] [Related]

  • 14. Liposomal amphotericin B for the treatment of severe fungal infection.
    Michaud D.
    Dynamics; 2001 Jul 13; 12(1):17-21. PubMed ID: 11982230
    [Abstract] [Full Text] [Related]

  • 15. Treatment outcomes in patients receiving conventional amphotericin B therapy: a prospective multicentre study in Taiwan.
    Chen CY, Kumar RN, Feng YH, Ho CH, You JY, Liao CC, Tseng CH, Mavros P, Gerth WC, Chen YC.
    J Antimicrob Chemother; 2006 Jun 13; 57(6):1181-8. PubMed ID: 16595642
    [Abstract] [Full Text] [Related]

  • 16. Nephrotoxicity of antifungal agents.
    Yang DJ, Rankin GO.
    Adverse Drug React Acute Poisoning Rev; 1985 Jun 13; 4(1):37-47. PubMed ID: 3890481
    [No Abstract] [Full Text] [Related]

  • 17. Lipid formulations of amphotericin B preserve and stabilize renal function in HSCT recipients.
    Miller CB, Waller EK, Klingemann HG, Dignani MC, Anaissie EJ, Cagnoni PJ, McSweeney P, Fleck PR, Fruchtman SM, McGuirk J, Chao NJ.
    Bone Marrow Transplant; 2004 Mar 13; 33(5):543-8. PubMed ID: 14730342
    [Abstract] [Full Text] [Related]

  • 18. [Analysis of the use of liposomal amphotericin B].
    González Martínez M, Mariño Martínez C, Baldominos Utrilla G, Fernández Martínez MN.
    Rev Iberoam Micol; 2014 Mar 13; 31(2):109-13. PubMed ID: 23711815
    [Abstract] [Full Text] [Related]

  • 19. Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study.
    Cordonnier C, Mohty M, Faucher C, Pautas C, Robin M, Vey N, Monchecourt F, Mahi L, Ribaud P.
    Int J Antimicrob Agents; 2008 Feb 13; 31(2):135-41. PubMed ID: 18162375
    [Abstract] [Full Text] [Related]

  • 20. Characterizing and predicting amphotericin B-associated nephrotoxicity in bone marrow or peripheral blood stem cell transplant recipients.
    Gubbins PO, Penzak SR, Polston S, McConnell SA, Anaissie E.
    Pharmacotherapy; 2002 Aug 13; 22(8):961-71. PubMed ID: 12173799
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.